Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | HTT | P42858 | 7/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 9/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404673 | 0.86 | ALDH1A1 (0.53) | MAPTALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL5408821 | 0.86 | MAOB (0.55) | MAPTALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL5406834 | 0.86 | ALDH1A1 (0.51) | MAPTALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL4000388 | 0.84 | ALDH1A1 (0.64) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL6578291 | 0.83 | ALDH1A1 (0.80) | MAPTALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL5412083 | 0.81 | ALDH1A1 (0.50) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL8983566 | 0.81 | MEN1 (0.74) | MAPTALDH1A1KMT2AMEN1ALOX12 | |
| SCHEMBL5408431 | 0.81 | IDO1 (0.44) | MAPTALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL7028772 | 0.81 | KMT2A (0.77) | MAPTALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL8983529 | 0.80 | HPGD (0.64) | MAPTALDH1A1HTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005044810-A1 | GLYT2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | MAPT 450/4885ALDH1A1 3023/4885HTT 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.